Prof Nicolas Mottet speaks to ecancer at the EMUC 2019 meeting in Vienna about the management of prostate cancer in older patients.

He gives an update on the SIOG guidelines and the new clinical trial data that supported these changes.

Prof Mottet also explores the classification of these patients as a means of valid decision-making, and the definition of "frailty" and "reversibility".

He concludes by discussing the applicability of these guidelines in under-resourced settings.

This service has been kindly supported by unrestricted grants from Janssen Oncology and Sanofi Genzyme.